Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients
- PMID: 34632574
- DOI: 10.1111/bjd.20805
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients
Abstract
Background: A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome').
Objectives: To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome.
Methods: One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded.
Results: The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis.
Conclusions: VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.
© 2021 British Association of Dermatologists.
Comment in
-
Working towards a better understanding of VEXAS syndrome.Br J Dermatol. 2022 Mar;186(3):392-393. doi: 10.1111/bjd.20949. Epub 2022 Mar 1. Br J Dermatol. 2022. PMID: 35230698 No abstract available.
References
-
- Beck DB, Ferrada MA, Sikora KA et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020; 383:2628-38.
-
- van der Made CI, Potjewijd J, Hoogstins A et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of VEXAS patients. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2021.05.014.
-
- Ferrada MA, Sikora KA, Luo Y et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS syndrome. Arthritis Rheumatol 2021; 73:1886-95.
-
- Tsuchida N, Kunishita Y, Uchiyama Y et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220090.
-
- Bourbon E, Heiblig M, Gerfaud-Valentin M et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 2021; 137:3682-4.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous